Serplulimab Combined with Chemotherapy in Patients with Resectable Esophageal Squamous Cell Carcinoma

Launched by SECOND AFFILIATED HOSPITAL, SCHOOL OF MEDICINE, ZHEJIANG UNIVERSITY · Dec 20, 2022

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment approach for patients with resectable esophageal squamous cell carcinoma, a type of cancer that starts in the esophagus. The researchers want to find out if combining a medication called serplulimab, which helps boost the immune system, with chemotherapy (a common cancer treatment) can improve outcomes before surgery. The goal is to see if this combination can help shrink the tumors and reduce the chance of the cancer coming back after surgery.

To be eligible for the trial, participants must be between 18 and 75 years old, have a confirmed diagnosis of esophageal squamous cell carcinoma that can be surgically removed, and have no signs of cancer spreading to other parts of the body. They should also be in good overall health, as assessed by a doctor. Participants can expect to receive the combination treatment and will be monitored closely for its effectiveness and any side effects. This trial is important because it could lead to better treatment options for patients facing this challenging disease.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. signed informed consent;
• • 2. patients age 18 to 75 years old
• • 3. primary resectable, histologically confirmed esophageal squamous cell cancer;
• • 4. Esophageal squamous cell carcinoma the clinical stage was IIA-IVA (according to AJCC TNM stage, 8th edition).
• • 5. ECOG PS 0-1.
• • 6. No distant metastasis, the diseases could be resectable assessed by thoracic oncologist;
• Exclusion Criteria:
• • 1. with significant cardiovascular disease;
• • 2. current treatment with anti-viral therapy or HBV;
• • 3. Female patients who are pregnant or lactating;
• • 4. history of malignancy within 5 years prior to screening;
• • 5. active or history of autoimmune disease or immune deficiency;
• • 6. signs of distant metastases.

Trial Officials